IVI reports “promising results” – needle-free candidate universal flu vaccine

The International Vaccine Institute (IVI) reported “promising results in mice on a needle-free candidate universal vaccine against seasonal and pandemic influenza.” IVI scientists “have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 (“swine flu”) virus.” The study was led by IVI scientist Dr. Man-ki Song and Dr. Haryoung Poo from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), and supported by the National Agenda Project of the Korea Research Council of Fundamental Science and Technology. Dr Christian Loucq, IVI Director-General, said, “Since pandemic influenza remains a global threat and would most likely start in the Asia-Pacific region, this study underscores IVI and the Republic of Korea’s commitments to join global efforts to build preparedness for and response to pandemic influenza.”

PLoS ONE article: Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027953

http://www.ivi.org/